SARS-CoV-2 viral protection drug efficacy evaluation clinical study

Clinical research related to the drugs with protective action against viral infections (SARS-CoV-2)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031230405

Enrollment

Registered

2023-10-17

Start date

2023-10-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 COVID-19

Interventions

Application of drug

D017387

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.SARS-CoV-2 positive patient(less than severity type II) 2.Written informed consent 3.Over age 20 at the time of informed consent

Exclusion criteria

Exclusion criteria: 1. Those who have been more than 10 days since the onset of COVID-19, or those with a negative SARS-CoV-2 PCR. 2. Pregnant or possibly pregnant or lactating patients 3. Who are unable to perform the PCR test by themselves. 4. Who has used any research drug within 1 week of the start of the study 5. Any other person whom the principal investigator or sub-investigator determines to be inappropriate to conduct this study.

Design outcomes

Primary

Measure	Time frame
Safety Assessment	—

Secondary

Measure	Time frame
Improvement of the symptom and change (%) in COVID-19 PCR values (before treatment) after 4 days of treatment	—

Contacts

Public ContactGen Takagi

Nippon Medical School Hospital

gen52@nms.ac.jp+81-3-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026